Member of the Association of American Physicians
Adrian F. Hernandez focuses on Heart failure, Internal medicine, Cardiology, Intensive care medicine and Emergency medicine. His work on Ejection fraction as part of general Heart failure research is frequently linked to In patient, bridging the gap between disciplines. His Internal medicine research is multidisciplinary, incorporating elements of Placebo and Surgery.
His Cardiology study frequently intersects with other fields, such as Endocrinology. His research in Intensive care medicine focuses on subjects like Epidemiology, which are connected to Cohort study. His Emergency medicine research incorporates elements of Logistic regression, Medicare beneficiary, Stroke, Statistic and Quality management.
Adrian F. Hernandez mainly investigates Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction. His work investigates the relationship between Heart failure and topics such as Emergency medicine that intersect with problems in Medicaid. His research related to Hazard ratio, Atrial fibrillation, Stroke, Odds ratio and Proportional hazards model might be considered part of Internal medicine.
His Stroke research includes themes of Physical therapy and Surgery. The concepts of his Cardiology study are interwoven with issues in Retrospective cohort study and Renal function. Adrian F. Hernandez has researched Intensive care medicine in several fields, including Quality of care, Randomized controlled trial and Heart disease.
Adrian F. Hernandez mostly deals with Internal medicine, Heart failure, Cardiology, Ejection fraction and Clinical trial. His Internal medicine research is multidisciplinary, relying on both Diabetes mellitus and Placebo. In his study, which falls under the umbrella issue of Heart failure, Prospective cohort study is strongly linked to Cohort study.
His Cardiology study combines topics from a wide range of disciplines, such as Stroke and Renal function. His studies deal with areas such as Valsartan, Quality of life and Interquartile range as well as Ejection fraction. In his study, Intensive care medicine is inextricably linked to Randomized controlled trial, which falls within the broad field of Clinical trial.
His scientific interests lie mostly in Internal medicine, Heart failure, Cardiology, Ejection fraction and Clinical trial. His Internal medicine study integrates concerns from other disciplines, such as Diabetes mellitus and Placebo. His work on Heart failure with preserved ejection fraction as part of general Heart failure study is frequently linked to In patient, therefore connecting diverse disciplines of science.
The study incorporates disciplines such as Stroke and Renal function in addition to Cardiology. The various areas that he examines in his Ejection fraction study include Medical therapy, Quality of life, Confidence interval, Angiotensin receptor and Valsartan. His studies in Clinical trial integrate themes in fields like Research design, Guideline and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diuretic Strategies in Patients with Acute Decompensated Heart Failure
G. Michael Felker;Kerry L. Lee;David A. Bull;Margaret M. Redfield.
The New England Journal of Medicine (2011)
Effect of nesiritide in patients with acute decompensated heart failure.
C. M. O'Connor;R. C. Starling;A. F. Hernandez;P. W. Armstrong.
The New England Journal of Medicine (2011)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R. Holman;M. Angelyn Bethel;Robert J. Mentz;Vivian P. Thompson.
The New England Journal of Medicine (2017)
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure.
Adrian F. Hernandez;Melissa A. Greiner;Gregg C. Fonarow;Bradley G. Hammill.
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial
Margaret M. Redfield;Horng H. Chen;Barry A. Borlaug;Marc J. Semigran.
Ultrafiltration in decompensated heart failure with cardiorenal syndrome
Bradley A. Bart;Steven R. Goldsmith;Kerry L. Lee;Michael M. Givertz.
The New England Journal of Medicine (2012)
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke
Jeffrey L. Saver;Gregg C. Fonarow;Eric E. Smith;Mathew J. Reeves.
Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes
Gregg C. Fonarow;Eric E. Smith;Jeffrey L. Saver;Mathew J. Reeves.
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino.
The Lancet (2018)
Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction Prevalence, Therapies, and Outcomes
Benjamin A. Steinberg;Xin Zhao;Paul A. Heidenreich;Eric D. Peterson.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: